Co-incubation of Vudalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vudalimab was able to block the PD-1/PD-L1 signaling pathway.

Vudalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Vudalimab bound to huPD-1-Jurkat cells, and the EC50 was 2.508 nM.

Vudalimab bound to CTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Vudalimab bound to CTLA4-CHO-K cells, and the EC50 was 20.150 nM.

Vudalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vudalimab bound to huPD-1-His, and the EC50 was 0.090 nM.

Vudalimab bound to CTLA4 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vudalimab bound to hu-CTLA4-His, and the EC50 was 0.480 nM.

The purity of Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) is 98.25%, determined by SEC-HPLC.

Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The detected molecular weight of Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) is 125.32 kDa.